FF 86 Atacicept for IgAN. Third attempt

About this episode

This episode discusses the Phase 3 trial of Atacicept for the treatment of IgA Nephropathy with insights from experts in renal medicine.

The Filtrate Joel Topf ‍ ‍ @kidneyboy.bsky.social‬ ( COI ) Sophia Ambruso @sophia-kidney.bsky.social Swapnil Hiremath @hswapnil.medsky.social and on LinkedIn Special Guests Jonathan Barratt Professor of Renal Medicine, University of Leicester Google Scholar (COI: all the companies) Editing and Show Notes by Nayan Arora @captainchloride.bsky.social The Kidney Connection written and performed by Tim Yau Show Notes Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy (Aliza Thompson, 2019 PubMed ) The number, quality, and coverage of randomized controlled trials in nephrology ( PubMed 2004 ) A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction ( PubMed 2017) BLISS Be limumab in lupus nephritis ( Neph JC | P ubMed ) The Phase 2 trial of atacicept A phase 2b, randomized, double -blind, pl acebo-controlled, clinical trial of at acicep t for trea tment of IgA nephropathy ( PubMed ) The phase 3 trial of atacicept, the subject of this podcast A Phase 3 Trial of Atacicept in Patients with IgA Nephr opathy (Pu bMed | NephJC ) The use of Gd-Ig A1 in the Testing Trial Role of Systemic Glucocorticoids in Reducing IgA and…

People in this episode

Host: Joel Topf

Guests: Sophia Ambruso, Swapnil Hiremath, Jonathan Barratt

Topics covered

• IgA Nephropathy
• Clinical Trials
• Renal Medicine
• Atacicept
• Proteinuria

Keywords

• Atacicept
• IgA Nephropathy
• Clinical Trials
• Proteinuria
• Renal Medicine

Mentioned in this episode

Organizations: University of Leicester, NephJC

Books & works: The Kidney Connection, Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy, The number, quality, and coverage of randomized controlled trials in nephrology, A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction, BLISS Be limumab in lupus nephritis, The Phase 2 trial of atacicept, A Phase 3 Trial of Atacicept in Patients with IgA Nephropathy, Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy, Updates to the KDIGO Guidelines for the treatment of IgA nephropathy

More episodes of Freely Filtered, a NephJC Podcast

• FF92 Live from Dublin, The Irish Nephrology Society · June 9, 2026 · 1h 36m
• FF91 Liberate-D · March 30, 2026 · 1h 36m
• FF90 NephMadness 2026: Animal House · March 21, 2026 · 1h 25m
• FF 89 Top Stories of 2025 · January 31, 2026 · 1h 51m
• FF 88 BICARICU-2, Bicarbonate in the ICU, still not helpful? · December 27, 2025 · 1h 25m
• FF 87 Can Fish Oil Knock the Crap out of Dialysis Associated CV Disease? · December 14, 2025 · 1h 20m